BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


View Clinical Trials from BioPharm Insight

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at

 Key Statistics

Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN



 Company News
Medivation, Inc. (MDVN) CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner 11/19/2014 5:22:47 PM
Dr. David Hung, Founder, President And CEO Of Medivation, Inc. (MDVN), Named EY Entrepreneur Of The Year™ 2014 National Overall Award Winner 11/17/2014 12:06:13 PM
Medivation, Inc. (MDVN) Reports Third Quarter Financial Results And Provides Corporate Update 11/7/2014 12:17:12 PM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 11/6/2014 1:55:09 PM
Medivation, Inc. (MDVN) And Astellas Pharma US Announce Phase 3 Study Of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy 10/31/2014 12:45:31 PM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 10/29/2014 12:23:14 PM
Medivation, Inc. (MDVN) Announces Third Quarter 2014 Financial Results Teleconference On November 6, 2014 10/27/2014 1:58:57 PM
Medivation, Inc. (MDVN) Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. For Potential Applications In Oncology 10/24/2014 11:32:11 AM
Wall Street Bullish On Medivation, Inc. (MDVN) After Xtandi Approval 9/12/2014 6:47:54 AM
Medivation, Inc. (MDVN) Banks $90 Million From Astellas Pharma Inc. (ALPMY) As FDA Expands Use Of Prostate Cancer Drug 9/11/2014 9:15:46 AM